Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05052528 |
|---|---|
| Brief Title: | Fludarabine and Cyclophosphamide With or Without Rituximab Before CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| First Submitted : | September 13, 2021 |
| First Submitted that Met QC Criteria : | September 13, 2021 |
| First Posted : | September 22, 2021 |
| Last Update Submitted that Met QC Criteria : | March 8, 2022 |
| Last Update Posted : | March 10, 2022 |